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first course, no dose-limiting toxicity occurred in any of 
the patients. grade 4 neutropenia was observed in two of 
three patients at level 4. at level 4, the antitumor effect 
was a partial response (Pr) in two of the three patients 
and stable disease (SD) in one. at level 3, one of the three 
patients showed Pr and two had SD. at level 4, the start of 
the next course was postponed in two of three patients. In 
addition, one patient at level 4 experienced hemotoxicity 
that met the criteria for dose reduction in the next course. 
the above results suggested that administration of CPt-11 
at dose level 5 (90 mg/m2) would result in more patients 
with severe neutropenia and in more patients requir-
ing postponement of the next course or a dose reduction. 
Based on the above, the rD of CPt-11 was determined to 
be 80 mg/m2.
Conclusions the results suggest that CPt-11/PlD com-
bination therapy for recurrent ovarian cancer is a useful 
treatment method with a high response rate and managea-
ble adverse reactions. In the future phase II study, the safety 
and efficacy of this therapy will be assessed at 80 mg/m2 of 
CPt-11 and 30 mg/m2 of PlD.
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Introduction
the standard initial chemotherapy for advanced ovarian 
cancer is paclitaxel plus carboplatin (tC) combination ther-
apy [1–3]. However, no treatment regimen for second-line 
chemotherapy has yet been established against recurrence 
after tC therapy. Various attempts are currently being made 
using, as criteria, the type of recurrence and the period 
from the last treatment until recurrence. Since recurrent 
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ovarian cancer with a treatment-free interval (the period 
from the end of the initial chemotherapy until recurrence) 
of <6 months is considered to be platinum resistant, it will 
be essential to select drugs not showing cross-resistance 
with the initial therapy. In the United States and europe, 
the type I Dna topoisomerase inhibitor topotecan [4], 
pegylated liposomal doxorubicin (PlD) [5], and gemcit-
abine [6] are used against platinum-resistant recurrent ovar-
ian cancer. In a Japanese phase II study involving patients 
with ovarian cancer previously treated with chemotherapy 
including platinum-based agents, PlD was reported to 
achieve an overall response rate of 21.9 % (27.3 % [3/11] 
in the platinum-sensitive group and 21.0 % [13/62] in the 
platinum-resistant group) [7]. In a phase III non-inferiority 
study comparing PlD with topotecan, it was reported that 
in patients treated with PlD, the response rate was 19.7 %, 
median progression-free survival (PFS) was 16.1 weeks, 
and mean survival time (MSt) was 60.0 weeks and, in 
patients with platinum-resistant tumors in particular, the 
response rate was 12.3 %, median PFS was 9.1 weeks, and 
MSt was 35.6 weeks [8], suggesting that PlD would be 
a promising therapeutic agent for recurrent ovarian can-
cer. On the other hand, irinotecan hydrochloride (CPt-11), 
an anticancer agent developed in Japan, acts by inhibit-
ing topoisomerase I. In a study in which CPt-11 (100 mg/
m2) alone was administered to patients with platinum-
resistant recurrent ovarian cancer, the response rate was 
29 %, the tumor growth inhibition rate (complete response 
[Cr] + partial response [Pr] + not changed) was 61 %, 
median time to progression was 17 weeks, and MSt was 
8 months, exhibiting favorable results [9]. Sugiyama et al. 
[10] reported that CPt-11/cisplatin therapy was effective 
as second-line chemotherapy for recurrent ovarian cancer 
after treatment with a platinum agent, raising the expecta-
tion that CPt-11 may be effective against platinum- and 
taxane-resistant tumors.
Herein, we conducted a phase I clinical study to deter-
mine the maximum tolerated dose (MtD) and the recom-
mended dose (rD) of CPt-11 in CPt-11/PlD combina-
tion therapy, a novel treatment regimen for platinum- and 
taxane-resistant recurrent ovarian cancer, with the aim of 
improving the outcomes of ovarian cancer patients.
Subjects and methods
Study population
Upon receiving approval from the intramural ethics com-
mittee of each study center, a multicenter clinical study 
was conducted in patients with recurrent ovarian cancer 
who met the following criteria and were enrolled in the 
study during the period from april 2010 to March 2013: 
(1) ovarian cancer confirmed by histological or cytological 
diagnosis, (2) recurrence less than 6 months after previous 
chemotherapy, (3) containing a measurable or evaluable 
lesion (including Ca-125 level), (4) eCOg performance 
status (PS) 0–2, (5) 20–75-year old, (6) expected survival 
time of at least 2 months, (7) major organs remained func-
tional (white blood cell count ≥3,000/mm3, neutrophil 
count ≥1,500/mm3, platelet count ≥10,0000/mm3, total 
bilirubin ≤1.5 mg/dl), and (8) informed consent provided. 
exclusion criteria were (1) serious complication(s), (2) 
evident pulmonary fibrosis or interstitial pneumonitis, (3) 
pleural or cardiac effusion necessitating prompt local treat-
ment, (4) brain metastasis requiring prompt treatment, (5) 
diarrhea (watery stool), (6) intestinal paralysis or intestinal 
obstruction, (7) active infection requiring treatment with 
antimicrobial agents, and (8) patients considered inappro-
priate as subjects by the physician in charge for any other 
reason.
Protocol
Pegylated liposomal doxorubicin was administered intrave-
nously at a fixed dose of 30 mg/m2 on day 3. CPt-11 was 
administered intravenously on days 1 and 15. One course of 
chemotherapy was 28 days, and as a general rule, patients 
were given at least 2 courses, 6 courses at the maximum.
Method for dose escalation
CPt-11 was started at level 1 (50 mg/m2) and then 
increased up to level 4 (80 mg/m2) (table 1). a group of 
three patients were given the same dose level of CPt-11, 
and if no dose-limiting toxicity (Dlt) was observed in any 
of them, the dose was increased to the next level. If Dlt 
was observed in one of the three patients at the same level, 
three additional patients were treated at the same dose level, 
and if there was no observable Dlt in at least three of the 
total six patients, the dose was increased to the next level. If 
Dlt was observed in at least three of the total six patients, 
the dose was judged to be MtD. If Dlt was observed 
in two of three patients at any level, this dose level was 
judged to be MtD. the dose that was 1 level below MtD 
was determined to be rD. Dlt was defined as (1) grade 
Table 1  Dose escalation schema
CPt-11 (mg/m2) PlD (mg/m2)
level 0 40 30
level 1 50 30
level 2 60 30
level 3 70 30
level 4 80 30
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4 leukopenia or neutropenia lasting for at least 4 days, (2) 
grade 3 or higher leukopenia or neutropenia accompanied 
by pyrexia of ≥38 °C, (3) grade 4 or higher thrombocyto-
penia or thrombocytopenia requiring platelet transfusion, 
or (4) grade 3 or higher nonhematological toxicity (except 
nausea/vomiting, anorexia, and general malaise). adverse 
events were evaluated according to nCI-CtCae ver. 3, 
and MtD was determined during the first course.
Criteria for changing dosing schedule
If any of the following applied, CPt-11 administration on 
day 15 was to be postponed and the drug was to be admin-
istered on day 22 upon confirming recovery from the condi-
tion: (1) white blood cell count ≤2,000/mm3, (2) neutrophil 
count ≤1,000/mm3, (3) platelet count ≤75,000/mm3, or (4) 
grade 1 or higher diarrhea. If recovery from the condition 
was not seen on day 22, the second CPt-11 administra-
tion was to be skipped (not to be administered on day 29). 
the criteria for proceeding to the second and subsequent 
courses were (1) white blood cell count ≥3,000/mm3, (2) 
neutrophil count ≥1,500/mm3, (3) platelet count ≥100,000/
mm3, (4) total bilirubin ≤1.5 mg/dl, (5) diarrhea grade 0, 
and (6) grade 1 or lower hand-and-foot syndrome and sto-
matitis. If the patient met any of the above criteria, admin-
istration was to be performed after waiting for recovery for 
a maximum of 14 days. If recovery from these conditions 
was not seen after 14 days, the treatment was to be discon-
tinued. If the severity of hand-and-foot syndrome or stoma-
titis remained at grade 2 or higher after a 14-day postpone-
ment, PlD on day 3 in the next course was to be skipped.
Criteria for dose reduction
the doses of CPt-11 and PlD in the next course were 
reduced according to the severity of adverse reactions that 
occurred in the previous course. If grade 4 leukopenia, grade 
4 neutropenia, or grade 3 thrombocytopenia were observed 
in the previous course, CPt-11 was reduced by 10 mg/m2, 
and PlD by 7.5 mg/m2. If grade 2 or higher diarrhea, spas-
modic abdominal pain, or watery stool were observed, the 
CPt-11 dose was reduced by 10 mg/m2. If grade 3 hand-
and-foot syndrome or stomatitis was observed, the PlD dose 
was reduced by 7.5 mg/m2 regardless of whether or not these 
conditions improved before the start of the next course.
evaluation of antitumor effect
the antitumor effect was evaluated by imaging at the end 
of every two courses. For the evaluation of the antitu-
mor effect, the best response rate was calculated accord-




table 2 shows the background characteristics of 12 patients 
enrolled in this study during the period from april 2010 
through March 2013. all patients had been treated with 
taxane- or platinum-based agents as a part of the previous 
therapy.
adverse events
three patients were enrolled for each level, and none of 
them experienced Dlt in the first course. no grade 3 or 
higher neutropenia was observed at level 1. grade 4 leu-
kopenia was observed in one patient each at level 2 and 
level 3, and in two patients at level 4. no grade 3 or higher 
thrombocytopenia was observed at level 1 or 2. at level 
3, grade 3 thrombocytopenia was observed in one patient, 
and at level 4, two patients developed grade 2 thrombo-
cytopenia, while no grade 3 or higher thrombocytopenia 
Table 2  Patients characteristics (n=12)
TC paclitaxel/carboplatin, TP paclitaxel/cisplatin, DP docetaxel/cispl-
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was observed. the only grade 2 or higher nonhematologi-
cal toxicity was grade 2 hand-and-foot syndrome, which 
occurred in one patient at level 4 (table 3).
administration status
In total, 43 treatment courses were administered. table 4 
shows the status of postponement of the next course, dose 
skipping, and dose reduction in each patient. the start of 
the next course was postponed due to the lack of recovery 
from neutropenia in one patient each at levels 1, 3, and 4 
and in two patients at level 2. all of these patients started 
the next course within 7 days without using granulocyte 
colony-stimulating factor. Postponement of the next course 
due to the lack of recovery from hand-and-foot syndrome 
occurred in one patient at level 4, but the next course was 
started within 7 days.
CPt-11 on day 15 was skipped in one patient each 
at level 1 and level 4, with the rate of skipping this treat-
ment being 4.7 %. In the patient at level 1, CPt-11 admin-
istration in the second course was postponed because the 
neutrophil count on day 15 did not meet the criterion for 
administration, and the study was terminated during the 
second course at the discretion of the attending physician. 
In the patient at level 4, CPt-11 administration on day 15 
in the third course was postponed, and due to the lack of 
recovery from leukopenia, the study was terminated at the 
discretion of the attending physician.
Table 3  toxicities level l (n = 3) level 2 (n = 3) level 3 (n = 3) level 4 (n = 3)
toxicity grade 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Hematological
 leukopenia 0 3 0 0 0 2 1 0 0 2 1 0 0 2 1 0
 neutropenia 0 3 0 0 0 2 0 1 0 2 0 1 0 1 0 2
 thrombocytopenia 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0
 anemia 3 0 0 0 2 1 0 0 1 1 0 0 2 0 0 0
nonhematological
 Mucositis 1 0 0 0 1 0 0 0 0 0 0 0 3 0 0 0
 Hand foot 1 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0
 Diarrhea 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
 nausea 2 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0
 Vomiting 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
 appetite loss 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
Table 4  administration situation of CPt-11 and PlD
SAC serous adenocarcinoma, EMC endometrioid adenocarcinoma, CCC clear cell carcinoma, CR complete response, PR partial response, 
SD stable disease, PD progressive disease
Patient  
no.
level CPt-1l  
(mg/m2)
Stage Cell type total  
cycles
Delay cycles  
(day l)
Skip cycles  
(day l5)
Dose reduction
1 1 50 IIIc SaC 4 2
2 1 50 IIIc SaC 4
3 1 50 IIIc SaC 2 1
4 2 60 IIIc eM 4 2 CPt-11 (−10mg/m2), PlD 
(−7.5mg/m2)
5 2 60 IIIb SaC 4 1
6 2 60 IIIc CCC 4
7 3 70 IV SaC 4
8 3 70 IIc SaC 4
9 3 70 Ic CCC 2 1 CPt-11 (−10mg/m2), PlD 
(−7.5mg/m2)
10 4 80 Ic CCC 4 1
11 4 80 IIIc SaC 3 1 CPt-11 (−10mg/m2), PlD 
(−7.5mg/m2)
12 4 80 IIIc SaC 4
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CPt-11 and PlD doses were reduced in one patient 
each at levels 2, 3, and 4 because of grade 4 neutropenia 
in the previous course. the doses were reduced in the sec-
ond course in the patients at levels 2 and 3, and in the third 
course in the patient at level 4.
Determination of recommended dose
three patients were assigned to each dose level, and none of 
them experienced Dlt during the first course, precluding the 
determination of MtD. therefore, the individual cases were 
analyzed in detail. at level 4, grade 4 leukopenia was observed 
in two of three patients and grade 2 leukopenia in 1. the anti-
tumor effect at level 4 was a Pr in two of the three patients 
and stable disease (SD) in 1. the patient with SD had clear 
cell adenocarcinoma. at level 3, Pr was observed in one of the 
three patients and SD in 2. as regards treatment postponement 
at level 4, CPt-11 administration on day 1 was postponed in 
the fourth course in 1 patient, and day-1 administration in the 
second course and day-15 administration in the third course 
were postponed in 1 patient (treatment in this patient was ter-
minated due to the lack of recovery from adverse reactions). 
thus, postponement of the next course occurred in two of the 
three patients. In addition, in one patient at level 4, CPt-11 
and PlD doses were reduced in the third course because of 
grade 4 neutropenia in the previous course. these results sug-
gested that more severe neutropenia would occur if CPt-11 
is increased to level 5 (90 mg), although a greater antitumor 
effect could be achieved. also, it was expected that the start of 
the next course would be postponed, and the dose would have 
to be reduced in a greater number of patients. Based on the 
above considerations, it was concluded that the recommended 
CPt-11 dose should be 80 mg/m2.
antitumor effect
table 5 shows antitumor effects at each level. Cr was 
observed in one patient (8.3 %), Pr in six (50.0 %), SD in 
two (16.7 %), and PD in three (25.0 %), with the response 
rate being 58.3 % and the disease control rate 75.0 %.
Discussion
the combined use of the topo-I inhibitor CPt-11 and the 
topo-II inhibitor PlD is expected to be effective, as sug-
gested by their synergistic mechanisms of action. also, this 
combination therapy allows dose reductions in each drug as 
compared with the monotherapy doses, thereby reducing the 
severity and frequency of adverse events without decreas-
ing the antitumor effect. In light of the above, CPt-11/PlD 
is expected to be effective against recurrent or advanced 
ovarian cancer resistant to platinum or taxane agents. In 
the phase II clinical study on CPt-11 50 mg/m2 (days 1, 8, 
15) and doxorubicin (DXr) 40 mg/m2 (day 3) combination 
therapy for recurrent ovarian cancer, nishimura et al. [11] 
reported that the response rate was 23.5 % (Cr, 1 patient; 
Pr, 3 patients of 17 patients) and that the grade 3/4 adverse 
reactions observed were neutropenia (CPt-11, 52.9 %; 
DXr, 35.2 %), thrombocytopenia (5.9 %, 17.6 %), anemia 
(17.6 %, 0 %), and diarrhea (5.9 %, 0 %). In the present 
study, the rates of skipping CPt-11 on days 8 and 15 were 
6.0 and 22.0 %, respectively, and that of DXr on day 3 was 
4.0 %. In the phase II study on CPt-11/etoposide combina-
tion therapy for recurrent small-cell lung carcinoma, Masuda 
et al. [12] reported that 6 of 25 patients (24 %) received two 
doses of CPt-11(days 1 and 8 or days 1 or 15), and 3 of 25 
patients (12 %) could receive only one dose of CPt-11. By 
referring to the results of the two aforementioned phase II 
clinical studies, we designed an administration schedule 
for CPt-11/PlD combination therapy. If CPt-11 was to be 
administered on a weekly basis, it was anticipated that the 
rates of skipping on days 8 and 15 would be high, resulting in 
30–50 % of patients skipping day 15 administration. there-
fore, it was decided to administer CPt-11 on a biweekly 
basis (day 1, day 15). also, it was reported that, in giving 
combination therapy with a topo-I inhibiter and a topo-II 
inhibiter, these agents act competitively rather than syner-
gistically if administered simultaneously [13]. By also tak-
ing account of the finding that CPt-11 is metabolized in 72 h 
[14], it was decided that PlD would be administered on day 
3, as has been the case with combination therapy employing 
DXr. In past reports, the dose of PlD in the combination 
therapy for recurrent ovarian cancer was 25–30 mg/m2 [15, 
16]. While the recommended dose for PlD monotherapy is 
50 mg/m2, sufficient efficacy and reduced adverse reactions 
have also been reported at the dose of 40 mg/m2 [17]. there-
fore, in consideration of reduced adverse reactions such as 
hand-and-foot syndrome and mucositis, the PlD dose was 
fixed at 30 mg/m2. as to CPt-11, no clinical study results are 
available for the combination with PlD or doxorubicin by 
the biweekly method and its optimal dose is unknown, and 
enormous variation in the dose response of CPt-11 among 
individuals, in general, is known [18]; therefore, the dose of 
CPt-11 alone was increased. a phase I clinical study was 
Table 5  treatment response
CR complete response, PR partial response, SD stable disease, 
PD progressive disease
Cr Pr SD PD Overall response 
(%)
level 1 (n=3) 1 1 0 1 66.7
level 2 (n=3) 0 2 1 0 66.7
level 3 (n=3) 0 1 0 2 33.3
level 4 (n=3) 0 2 1 0 66.7
total (n=12) 1 6 2 3 58.3
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planned to investigate the efficacy and safety of CPt-11/PlD 
combination therapy for recurrent ovarian cancer.
adverse events were evaluated for each patient in the 
first course only. as shown in table 3, although adverse 
events were observed, all were nonserious and manage-
able. thus, the phase I clinical study could be conducted 
safely. Shoji et al. [19] reported that the rate of skipping 
CPt-11 on day 15 was 2.3 % with the combination ther-
apy based on CPt-11 (60 mg/m2) biweekly administration 
with etoposide oral administration for recurrent ovarian 
cancer. In our present study as well, CPt-11 was admin-
istered on a biweekly basis (days 1, 15), and as a result, 
day 15 administration was skipped in only 1 patient each 
at level 1 and level 4. thus, CPt-11 on day 15 was skipped 
in only 2 of a total of 43 courses, with the rate of skipping 
treatment being just 4.7 %, suggesting biweekly adminis-
tration of CPt-11 in CPt-11/PlD combination therapy to 
be appropriate. Since no Dlt was observed at any of the 
levels tested, it would be feasible to increase the dose of 
CPt-11 to level 5 under ordinary circumstances. However, 
as mentioned above, as a result of detailed evaluation of 
grade 4 neutropenia in three patients at level 4, postpone-
ment to the next course, dose reduction, and antitumor 
effect, the recommended CPt-11 dose was determined to 
be 80 mg/m2.
the response rate to combination therapy using CPt-
11 or PlD for platinum-resistant recurrent ovarian can-
cer is 41.9 % with CPt-11/VP16 therapy according to 
Shoji et al. [19] and 44.4 % according to nishio et al. 
[20], and 20 % with DtX/CPt-11 therapy according to 
Polyzos et al. [21]. the response rate was also reported 
to be 22 % with PlD/gemcitabine therapy by Skarlos 
et al. [22] and 40 % [23] by Mirza et al. the response 
rate to CPt-11/PlD combination therapy was 58.3 %, 
a result not inferior to those reported previously. all 12 
enrolled patients had previously been treated with taxane 
or platinum agents. In particular, eight of them had recur-
rence or recrudescence within 6 months after tC therapy. 
It is expected that CPt-11/PlD combination therapy will 
achieve a high response rate and that adverse reactions 
will be mild and manageable. this drug combination may 
thus be useful as an option for second-line chemotherapy 
for recurrent ovarian cancer within 6 months after tC 
therapy.
In the future, a phase II clinical study will be conducted to 
validate the usefulness of CPt-11/PlD combination therapy.
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